Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effects of terbinafine and itraconazole on the pharmacokinetics of orally administered tramadol.

European journal of clinical pharmacology - 1 Mar 2015

Saarikoski Tuukka, Saari Teijo I, Hagelberg Nora M, Backman Janne T, Neuvonen Pertti J, Scheinin Mika, Olkkola Klaus T, Laine Kari

Abstract excerpt

BACKGROUND: Tramadol is widely used for acute, chronic, and neuropathic pain. Its primary active metabolite is O-desmethyltramadol (M1), which is mainly accountable for the μ-opioid receptor-related analgesic effect. Tramadol is metabolized to M1 mainly by cytochrome P450 (CYP)2D6 enzyme and to other metabolites by CYP3A4 and CYP2B6. We investigated the possible interaction of tramadol with the antifungal agents...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Analgesics, Opioid

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cross-Over Studies

Share to Cytochrome P-450 CYP2D6 Inhibitors

Share to Cytochrome P-450 CYP3A Inhibitors

Share to Drug Interactions

Share to Itraconazole

Share to Naphthalenes

Source

Identifiers

PMID: 25560051
DOI: 10.1007/s00228-014-1799-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effects of terbinafine and itraconazole on the pharmacokinetics of orally administered tramadol.PMID 25560051Read ↗

Trends in Tramadol: Pharmacology, Metabolism, and Misuse.Semantic proximity Read ↗

Rifampicin markedly decreases the exposure to oral and intravenous tramadol.Semantic proximity Read ↗

Assessment of tramadol pharmacokinetics in correlation with CYP2D6 and clinical symptoms.Semantic proximity Read ↗

Physiologically based pharmacokinetic modeling of tramadol to inform dose adjustment and drug-drug interactions according to CYP2D6 phenotypes.Semantic proximity Read ↗

Influence of CYP2D6 phenotype on the pharmacokinetics and pharmacodynamics of tramadol in patients treated for post-operative pain management.Semantic proximity Read ↗

In vitro comparative analysis of metabolic capabilities and inhibitory profiles of selected CYP2D6 alleles on tramadol metabolism.Semantic proximity Read ↗

Involvement of CYP2D6 and CYP2B6 on tramadol pharmacokinetics.Semantic proximity Read ↗

Impact of CYP genotype and inflammatory markers on the plasma concentrations of tramadol and its demethylated metabolites and drug tolerability in cancer patients.Semantic proximity Read ↗

Pharmacokinetics of tramadol and its three main metabolites in healthy male and female volunteers.Semantic proximity Read ↗

Pharmacogenetics of trazodone in healthy volunteers: association with pharmacokinetics, pharmacodynamics and safety.Semantic proximity Read ↗

Enantioselective pharmacokinetics of tramadol and its three main metabolites; impact of CYP2D6, CYP2B6, and CYP3A4 genotype.Semantic proximity Read ↗

Role of Pharmacogenetics on Tramadol Pharmacokinetics: A Population Pharmacokinetic Model.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.